<?xml version="1.0" encoding="UTF-8"?>
<ref id="B139-biomolecules-11-00350">
 <label>139.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Huanga</surname>
    <given-names>S.H.</given-names>
   </name>
   <name>
    <surname>Dukea</surname>
    <given-names>R.D.</given-names>
   </name>
   <name>
    <surname>Chebibb</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Sasakic</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Wada</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Johnston</surname>
    <given-names>G.A.</given-names>
   </name>
  </person-group>
  <article-title>Bilobalide, a sesquiterpene trilactone from 
   <italic>Ginkgo biloba</italic>, is an antagonist at recombinant α
   <sub>1</sub>β
   <sub>2</sub>Ƴ
   <sub>2L</sub> GABA
   <sub>A</sub> receptors
  </article-title>
  <source>Eur. J. Pharmacol.</source>
  <year>2003</year>
  <volume>464</volume>
  <fpage>1</fpage>
  <lpage>8</lpage>
  <pub-id pub-id-type="doi">10.1016/S0014-2999(03)01344-X</pub-id>
  <pub-id pub-id-type="pmid">12600688</pub-id>
 </element-citation>
</ref>
